Forge Biologics Strengthens Genetic Medicine CDMO Capabilities

New leadership team appointments strengthen manufacturing capabilities with a focus on gene therapy clinical and commercial cGMP manufacturing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Forge Biologics, a gene therapy-focused CDMO, has added three key leadership roles to further the Company’s growth as a manufacturer of genetic medicines. Chris McPherson has been appointed Vice President of GMP Manufacturing, Taleen Barsoumian will serve as Vice President of Client Development, and Adam Davis, Ph.D., was promoted to Vice President of Analytical Development.   Chris McPherson will oversee clinical and commercial cGMP manufacturing operations of Forge’s 50L to 5,000L bioreactor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters